On Friday, Akebia Therapeutics Inc (NASDAQ: AKBA) was 1.65% up from the session before settling in for the closing price of $1.82. A 52-week range for AKBA has been $0.80 – $2.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 5.16%. When this article was written, the company’s average yearly earnings per share was at -1.19%. With a float of $207.61 million, this company’s outstanding shares have now reached $211.54 million.
The extent of productivity of a business whose workforce counts for 167 workers is very important to gauge. In terms of profitability, gross margin is 63.13%, operating margin of -20.45%, and the pretax margin is -27.07%.
Akebia Therapeutics Inc (AKBA) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Akebia Therapeutics Inc stocks. The insider ownership of Akebia Therapeutics Inc is 4.85%, while institutional ownership is 24.83%. The most recent insider transaction that took place on May 13 ’24, was worth 15,140. In this transaction SVP, Chief Legal Officer of this company sold 12,016 shares at a rate of $1.26, taking the stock ownership to the 651,243 shares. Before that another transaction happened on May 13 ’24, when Company’s SVP, Chief Operating Officer sold 34,840 for $1.26, making the entire transaction worth $43,898. This insider now owns 672,092 shares in total.
Akebia Therapeutics Inc (AKBA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -1.19% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
You can see what Akebia Therapeutics Inc (AKBA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.25 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
The latest stats from [Akebia Therapeutics Inc, AKBA] show that its last 5-days average volume of 2.2 million was inferior to 3.03 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 13.38%. Additionally, its Average True Range was 0.09.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 70.91%, which indicates a significant increase from 15.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.56% in the past 14 days, which was lower than the 63.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7351, while its 200-day Moving Average is $1.4442. Now, the first resistance to watch is $1.8767. This is followed by the second major resistance level at $1.9033. The third major resistance level sits at $1.9467. If the price goes on to break the first support level at $1.8067, it is likely to go to the next support level at $1.7633. The third support level lies at $1.7367 if the price breaches the second support level.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
There are 218,181K outstanding shares of the company, which has a market capitalization of 410.29 million. As of now, sales total 194,620 K while income totals -51,930 K. Its latest quarter income was 37,430 K while its last quarter net income were -20,040 K.
